Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Operating Income
Avadel Pharmaceuticals PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$42.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
7%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$311.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-7%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$726.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Operating Income
-$18.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$50.3m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-177%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
€86m
|
CAGR 3-Years
172%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Operating Income?
Operating Income
-42.4m
USD
Based on the financial report for Dec 31, 2024, Avadel Pharmaceuticals PLC's Operating Income amounts to -42.4m USD.
What is Avadel Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 10Y
7%
Over the last year, the Operating Income growth was 69%. The average annual Operating Income growth rates for Avadel Pharmaceuticals PLC have been 21% over the past three years , -19% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet